兴齐眼药SQ-24071滴眼液临床试验获批准

Core Viewpoint - The company, Xingqi Eye Medicine, has received approval from the National Medical Products Administration for the clinical trial of its eye drop product SQ-24071, aimed at delaying myopia progression in children and adolescents [1]. Group 1 - The announcement was made on January 19, indicating the company's ongoing commitment to developing innovative treatments for eye health [1]. - SQ-24071 is classified as a modified new drug of chemical drugs category 2.2 and 2.4, highlighting its potential significance in the pharmaceutical market [1]. - The clinical trial approval marks a critical step in the product's development, which could address a growing concern regarding myopia in younger populations [1].